Opinion: CMS needs to do FDA’s job and limit the use of Biogen’s pricey new Alzheimer’s drug
Now that the FDA has approved Biogen’s expensive new Alzheimer’s drug with little clinical benefit potential, but plenty of potential to speed the bankruptcy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
